NeoGenomics Inc. (NEO) Now Covered by Analysts at First Analysis
A number of other research firms have also weighed in on NEO. Zacks Investment Research raised NeoGenomics from a hold rating to a buy rating and set a $9.25 target price for the company in a research note on Thursday, July 7th. BTIG Research reissued a buy rating and issued a $10.00 target price on shares of NeoGenomics in a research note on Friday, July 8th. Craig Hallum reissued a buy rating on shares of NeoGenomics in a research note on Saturday, July 9th. Benchmark Co. boosted their target price on NeoGenomics from $10.00 to $12.00 and gave the company a buy rating in a research note on Wednesday, July 27th. Finally, Raymond James Financial Inc. began coverage on NeoGenomics in a research note on Thursday, September 8th. They issued an outperform rating and a $10.00 target price for the company. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $10.41.
Shares of NeoGenomics (NASDAQ:NEO) opened at 8.075 on Monday. The firm’s market cap is $628.99 million. NeoGenomics has a 52 week low of $5.49 and a 52 week high of $9.54. The firm has a 50-day moving average price of $8.11 and a 200-day moving average price of $8.09.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, July 26th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.01. NeoGenomics had a positive return on equity of 3.18% and a negative net margin of 3.76%. The firm earned $63.10 million during the quarter, compared to analyst estimates of $61.07 million. During the same quarter in the previous year, the company posted $0.01 earnings per share. The company’s revenue was up 159.0% compared to the same quarter last year. On average, equities research analysts predict that NeoGenomics will post $0.13 earnings per share for the current year.
In other NeoGenomics news, insider Maher Albitar sold 60,075 shares of the company’s stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $8.23, for a total transaction of $494,417.25. Following the transaction, the insider now owns 165,375 shares in the company, valued at approximately $1,361,036.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in NeoGenomics by 0.9% in the first quarter. State Street Corp now owns 777,559 shares of the company’s stock worth $5,241,000 after buying an additional 7,266 shares during the period. Falcon Point Capital LLC increased its position in NeoGenomics by 12.5% in the second quarter. Falcon Point Capital LLC now owns 209,538 shares of the company’s stock worth $1,685,000 after buying an additional 23,216 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in NeoGenomics by 14,127.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 142,276 shares of the company’s stock worth $959,000 after buying an additional 141,276 shares during the period. Fox Run Management L.L.C. purchased a new position in NeoGenomics during the second quarter worth $171,000. Finally, Geode Capital Management LLC increased its position in NeoGenomics by 3.8% in the first quarter. Geode Capital Management LLC now owns 355,158 shares of the company’s stock worth $2,393,000 after buying an additional 13,052 shares during the period. Hedge funds and other institutional investors own 77.20% of the company’s stock.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.